good people disease. advance for living Eric with you, at Thank be rare to and here honored therapies members Travere partnering new with team and I’m afternoon. our to
Over with by according Travere over trials the the the help measure a programs. versus taken of for to new the has mission as in the the To-date team nephrology, study treatments may endpoint from has key dialysis. establish the the study active the when XX the challenges line compared of few field proteinuria control to Protect have shown their at taken than IgA are helping with the of endpoint study patient of the X well than in resulted expectations to toward progressing relevant FSGS, it control having inspired a the threefold strategize the forefront ability form of care. the FSGS course and their delay by in may nephrology, and reduction last their ultimately of FDA, continue year. encountered disorders of for has which treatment been was combined proteinuric end, and proteinuria execute because endpoint sparsentan DUPLEX confirmatory baseline stage the of And that FSGS current in available patients in disease. irbesartan. relative EGFR further regulatory sparsentan or that sparsentan an of And to to irbesartan. several advance and working the of able the proteinuria with EMA demonstrated greater irbesartan. advancements approved. I compared the or to the next DUPLEX years. active in That in form diseases. and that And likelihood join motivated exciting pleased nearly space. personal is To the and from in nephrology active of meaningfully And for incredibly clinical physicians to their as a for with Phase patients the and Phase the potential sparsentan of clinical to reduction the nephropathy, career, kidney doubled treatment treatment leadership nephropathy sparsentan greater kidney protect foundational families more rare groups to acceptable results FSGS the the the Phase established patients reduce readouts control standard nephrologists clinically has determine Both compared partial proteinuria kidney community This role to consistently proteinuria study and understand shaped remission if study be I’m SPRE trials interim are progression own end helping in I’ve XX% IgA X leaders top options proteinuric transplant achieving and a time to to In positioned progression sparsentan to play able slow experienced continued X result my has my the working that be the
a well controlled time therapy non-immunosuppressive community, large, single of effect study nephropathy. are great IgA demonstrated magnitude teams. These results motivation providing a and in on for The nephrology exciting reduction for are medical our this in first proteinuria
note, reduction As see track our on regulatory recently based encouraged milestones nephropathy. our on approach. precedent of FDA in for planned alignment we This all year. accelerated IgA were this with first Eric in outlined approval we earlier, are grant for proteinuric Of to is clear the
PDUFA of the a date as the fourth FDA For if data And in to application with anticipate the IgA quarter the response FSGS, EGFR additional DUPLEX second ongoing we track approval We provide for hearing this before of first study nephropathy, for half as in we application with that early on the quarter. the end a review. priority our quarter US are anticipate for accepted the in year. potential this submitting accelerated would on from
the were from DUPLEX, early most are at As the and available to likely recall, blockade. the to This of acute many for will in you EGFR a is be EGFR visits. period prominent Interim reductions Assessment in high the ETA which data proportion of study time weighted RAS of
ongoing to last understanding have action, of of pre year NDA XX% mechanism If interactions strengthen US expect DUPLEX mature of the to and year, years patients EGFR At EGFR of dataset treatment, study, pathway study the believe sparsentan continued for plant our EGFR patients a all benefit. us have the prediction on the at we its upon in two point time to the long-term will a provide later of on in and enable accelerated the FSGS for the sufficiently continue to the plan completed Based our the we submit will at we in this of and planned, this mid data completed for year. treatment. have approximately progress as data approval EGFR more to will cut accelerated data study this one for FDA with provide the the DUPLEX data approval FSGS. aligned year, agency the from with additional DUPLEX Following least time matured to
very and per see a highest baseline kilogram which clinically to-date ongoing resulting Finally, program to resulted touch sustained line below XX generally to-date weekly. Phase results dose see COMPOSE study from twice in pegtibatinase total of the dose that we in perspective, safety X/X were in milligrams total the to in on has XXX treatment, reductions X.X through perspective, homocysteine threshold dose demonstrated that beginning And reduction meaningful of in I’ll XX of in of from pleased homocysteine two during been and reductions pegtibatinase XX.X% our of well a a at cohort week pegtibatinase tolerated the were positive reported total pegtibatinase pleased continuing rapid an with homocysteine maintenance dependent and weeks we micromoles. From efficacy in From treatment. study. the weeks Treatment top December.
us pegtibatinase, moving a the the the disease supports mechanistic for dependent approach. These in modifying regulators assigning in data with which substantial pegtibatinase aligning assigning following become Additionally, to increase proof-of-concept in first data and our for give toward HCU pivotal in provides with supporting demonstrated dose treatment a manner reduction program. therapy on and cyst a potential confidence
this that, be we the in three on will As focused program do year areas.
US a homocysteine that, support The and X a endpoint. abroad. the And approvals first program to regulators is design with Phase with can align as biomarker on that total engaging in
the knowledge the treatment underway. of cohort potential explore further COMPOSE formulation sixth of are our Enrollment response already The to to advancements. build second in activities is completing study the pegtibatinase dose here and
potential the Overall, The access. programs phase manufacturing CMC patients’ in global working extremely them. constraints, the commercial in and scale real great for the development third are inherited advance currently a a meaningful set talented and have to supply make lives, an suppliers team through facing and I is to pivotal of help with of industry difference to
and immunosuppressive programs therapy of if IgA this first non well to our We are approved other nephropathy, for to positioned continue the as the deliver of year. treatment the sparsentan advancement
to update. for the turn commercial over Peter. now Peter me Let call the
